bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Uric Acid and Neurocognitive Function in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only
Authors: Cheung Yin Ting , Edelmann Michelle N. , Mulrooney Daniel A. , Green Daniel M. , Chemaitilly Wassim , John Neena , Robison Leslie L. , Hudson Melissa M. , Krull Kevin R.
Published: April 2023

Abstract
Background: Hyperuricemia is implicated in cardiovascular and cerebrovascular diseases. This study evaluated associations between uric acid (UA), cardiovascular health, and neurocognitive function in adolescent and adult survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.

Methods: 126 adolescent [mean (SD) age 14.6 (5.0); 7.8 (1.7) years postdiagnosis] and 226 adult survivors [age 25.4 (4.2) years; 18.1 (4.4) years postdiagnosis] completed comprehensive neurocognitive testing. Concurrent UA measurements were conducted for both groups. For adult survivors, cardiovascular risk factors were assessed, and UA measurements during adolescence [12.3 (4.0) years before neurocognitive testing] were also collected. UA levels were categorized into quartiles for age- and gender-based ranking, and associations with neurocognitive outcomes were examined.

Results: Survivors demonstrated worse attention, processing speed, and executive functions than population norms (P values < 0.05). Adolescent survivors with elevated UA had poorer attention (P = 0.04), visual-processing speed (P = 0.03), and cognitive flexibility (P = 0.02). UA was not associated with neurocognitive outcomes in adult survivors. Adult survivors developed dyslipidemia (46%), hypertension (32%), and abdominal obesity (26%), and high UA during adolescence was associated with these cardiovascular risk factors as adults (all P values < 0.01). Fine-motor processing speed was slower in adult survivors with dyslipidemia (P = 0.04) and abdominal obesity (P = 0.04). Poorer attention was marginally associated with hypertension (P = 0.06).

Conclusions: Elevated UA is associated with neurocognitive performance in adolescent survivors. In adult survivors, relative elevation of UA during adolescence was predictive of cardiovascular health, which was associated with poorer neurocognitive outcomes.

Impact: Future studies should evaluate the mediating role of chronic cardiovascular health conditions between elevated UA and subsequent neurocognitive impairment in survivors. Cancer Epidemiol Biomarkers Prev; 25(8); 1259–67. ©2016 AACR.
Data from Longitudinal Change in Mammographic Density among ER-Positive Breast Cancer Patients Using Tamoxifen
Authors: Nyante Sarah J. , Sherman Mark E. , Pfeiffer Ruth M. , de Gonzalez Amy Berrington , Brinton Louise A. , Bowles Erin J. Aiello , Hoover Robert N. , Glass Andrew , Gierach Gretchen L.
Published: April 2023

Abstract
Tamoxifen-associated mammographic density (MD) reductions are linked to improved breast cancer survival. We evaluated MD at six time points to determine the timing of greatest reduction following tamoxifen initiation. We sampled 40 Kaiser Permanente Northwest estrogen receptor (ER)–positive breast cancer patients from a prior study of MD change, according to tamoxifen use duration and age at diagnosis: <4 years tamoxifen and ≤50 years (N = 6) or >50 years (N = 10) old; ≥4 years tamoxifen and ≤50 years (N = 13) or >50 years (N = 11) old. A single reader evaluated percent MD in the contralateral breast on baseline (pre-diagnosis) and five approximately yearly post-diagnostic (T1 to T5) mammograms. Mean MD change was calculated. Interactions with age (≤50 and >50 years), tamoxifen duration (<4 and ≥4 years), and baseline MD (tertiles) were tested in linear regression models. Overall, the largest MD decline occurred by T1 (mean 4.5%) with little additional decline by T5. Declines differed by tertile of baseline MD (Pinteraction < 0.01). In the highest tertile, the largest reduction occurred by T1 (mean 14.9%), with an additional reduction of 3.6% by T5. Changes were smaller in the middle and lowest baseline MD tertiles, with cumulative reductions of 3.0% and 0.4% from baseline to T5, respectively. There were no differences by age (Pinteraction = 0.36) or tamoxifen duration (Pinteraction = 0.42). Among ER-positive patients treated with tamoxifen and surviving ≥5 years, most of the MD reduction occurred within approximately 12 months of tamoxifen initiation, suggesting that MD measurement at a single time point following tamoxifen initiation can identify patients with substantial density declines. Cancer Epidemiol Biomarkers Prev; 25(1); 212–6. ©2015 AACR.
Data from The Expression of Four Genes as a Prognostic Classifier for Stage I Lung Adenocarcinoma in 12 Independent Cohorts
Authors: Okayama Hirokazu , Schetter Aaron J. , Ishigame Teruhide , Robles Ana I. , Kohno Takashi , Yokota Jun , Takenoshita Seiichi , Harris Curtis C.
Published: April 2023

Abstract
Background: We previously developed a prognostic classifier using the expression levels of BRCA1, HIF1A, DLC1, and XPO1 that identified stage I lung adenocarcinoma patients with a high risk of relapse. That study evaluated patients in five independent cohorts from various regions of the world. In an attempt to further validate the classifier, we have used a meta-analysis–based approach to study 12 cohorts consisting of 1,069 tumor–node–metastasis stage I lung adenocarcinoma patients from every suitable, publically available dataset.

Methods: Cohorts were obtained through a systematic search of public gene expression datasets. These data were used to calculate the risk score using the previously published 4-gene risk model. A fixed effect meta-analysis model was used to generate a pooled estimate for all cohorts.

Results: The classifier was associated with prognosis in 10 of the 12 cohorts (P < 0.05). This association was highly consistent regardless of the ethnic diversity or microarray platform. The pooled estimate demonstrated that patients classified as high risk had worse overall survival for all stage I [HR, 2.66; 95% confidence interval (CI), 1.93–3.67; P < 0.0001] patients and in stratified analyses of stage IA (HR, 2.69; 95% CI, 1.66–4.35; P < 0.0001) and stage IB (HR, 2.69; 95% CI, 1.74–4.16; P < 0.0001) patients.

Conclusions: The 4-gene classifier provides independent prognostic stratification of stage IA and stage IB patients beyond conventional clinical factors.

Impact: Our results suggest that the 4-gene classifier may assist clinicians in decisions about the postoperative management of early-stage lung adenocarcinoma patients. Cancer Epidemiol Biomarkers Prev; 23(12); 2884–94. ©2014 AACR.
Data from Dietary Intake of One-Carbon Metabolism–Related Nutrients and Pancreatic Cancer Risk: The Singapore Chinese Health Study
Authors: Huang Joyce Y. , Butler Lesley M. , Wang Renwei , Jin Aizhen , Koh Woon-Puay , Yuan Jian-Min
Published: April 2023

Abstract
Background: Nutrients involved in one-carbon metabolism are hypothesized to protect against pancreatic cancer development.

Methods: The Singapore Chinese Health Study database was used to prospectively examine the association between intake of one-carbon metabolism–related nutrients and pancreatic cancer risk. Between 1993 and 1998, 63,257 men and women ages 45 to 74 years were enrolled into the cohort. The daily intakes of the following one-carbon metabolism–related nutrients were assessed at enrollment using a 165-item food frequency questionnaire: betaine, choline, folate, and vitamins B2, B6, and B12. Multivariable HRs and 95% confidence intervals (CI) for pancreatic cancer risk associated with dietary intakes of one-carbon metabolism–related nutrients were calculated.

Results: As of December 2013, 271 incident pancreatic cancer cases were identified during an average of 16.3 years of follow-up. Higher intakes of vitamin B6 and choline were associated with statistically significant decreases in the risk of developing pancreatic cancer. Compared with the lowest quartile, HRs (95% CIs) for the highest quartiles of vitamin B6 and choline were 0.52 (0.36–0.74; P trend = 0.001) and 0.67 (0.48–0.93; P trend = 0.04), respectively. There were no clear associations between the other one-carbon metabolism–related nutrients and pancreatic cancer risk.

Conclusion: Our study suggests that higher intake of vitamin B6 and choline may lower the risk of pancreatic cancer.

Impact: Our prospective findings are consistent with the in vivo evidence for protective roles of vitamin B6 and choline on pancreatic cancer development. Cancer Epidemiol Biomarkers Prev; 25(2); 417–24. ©2015 AACR.
Data from Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study
Authors: E Jian-Yu , Lu Shou-En , Lin Yong , Graber Judith M. , Rotter David , Zhang Lanjing , Petersen Gloria M. , Demissie Kitaw , Lu-Yao Grace , Tan Xiang-Lin
Published: April 2023

Abstract
Background: Published evidence indicates that individual use of metformin and statin is associated with reduced cancer mortality. However, their differential and joint effects on pancreatic cancer survival are inconclusive.

Methods: We identified a large population-based cohort of 12,572 patients ages 65 years or older with primary pancreatic ductal adenocarcinoma (PDAC) diagnosed between 2008 and 2011 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Exposure to metformin and statins was ascertained from Medicare Prescription Drug Event files. Cox proportional hazards models with time-varying covariates adjusted for propensity scores were used to assess the association while controlling for potential confounders.

Results: Of 12,572 PDAC patients, 950 (7.56%) had used metformin alone, 4,506 (35.84%) had used statin alone, and 2,445 (19.45%) were dual users. Statin use was significantly associated with improved overall survival [HR, 0.94; 95% confidence interval (CI), 0.90–0.98], and survival was more pronounced in postdiagnosis statin users (HR, 0.69; 95% CI, 0.56–0.86). Metformin use was not significantly associated with overall survival (HR, 1.01; 95% CI, 0.94–1.09). No beneficial effect was observed for dual users (HR, 1.00; 95% CI, 0.95–1.05).

Conclusions: Our findings suggest potential benefits of statins on improving survival among elderly PDAC patients; further prospective studies are warranted to corroborate the putative benefit of statin therapy in pancreatic cancer.

Impact: Although more studies are needed to confirm our findings, our data add to the body of evidence on potential anticancer effects of statins. Cancer Epidemiol Biomarkers Prev; 26(8); 1225–32. ©2017 AACR.
Data from Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study
Authors: Amirian E. Susan , Zhou Renke , Wrensch Margaret R. , Olson Sara H. , Scheurer Michael E. , Il'yasova Dora , Lachance Daniel , Armstrong Georgina N. , McCoy Lucie S. , Lau Ching C. , Claus Elizabeth B. , Barnholtz-Sloan Jill S. , Schildkraut Joellen , Ali-Osman Francis , Sadetzki Siegal , Johansen Christoffer , Houlston Richard S. , Jenkins Robert B. , Bernstein Jonine L. , Merrell Ryan T. , Davis Faith G. , Lai Rose , Shete Sanjay , Amos Christopher I. , Melin Beatrice S. , Bondy Melissa L.
Published: April 2023

Abstract
Background: Several previous studies have found inverse associations between glioma susceptibility and a history of allergies or other atopic conditions. Some evidence indicates that respiratory allergies are likely to be particularly relevant with regard to glioma risk. Using data from the Glioma International Case-Control Study (GICC), we examined the effects of respiratory allergies and other atopic conditions on glioma risk.

Methods: The GICC contains detailed information on history of atopic conditions for 4,533 cases and 4,171 controls, recruited from 14 study sites across five countries. Using two-stage random-effects restricted maximum likelihood modeling to calculate meta-analysis ORs, we examined the associations between glioma and allergy status, respiratory allergy status, asthma, and eczema.

Results: Having a history of respiratory allergies was associated with an approximately 30% lower glioma risk, compared with not having respiratory allergies (mOR, 0.72; 95% confidence interval, 0.58–0.90). This association was similar when restricting to high-grade glioma cases. Asthma and eczema were also significantly protective against glioma.

Conclusion: A substantial amount of data on the inverse association between atopic conditions and glioma has accumulated, and findings from the GICC study further strengthen the existing evidence that the relationship between atopy and glioma is unlikely to be coincidental.

Impact: As the literature approaches a consensus on the impact of allergies in glioma risk, future research can begin to shift focus to what the underlying biologic mechanism behind this association may be, which could, in turn, yield new opportunities for immunotherapy or cancer prevention. Cancer Epidemiol Biomarkers Prev; 25(2); 282–90. ©2016 AACR.
Data from Risk Factors for Oral HPV Infection among a High Prevalence Population of HIV-Positive and At-Risk HIV-Negative Adults
Authors: Beachler Daniel C. , Weber Kathleen M. , Margolick Joseph B. , Strickler Howard D. , Cranston Ross D. , Burk Robert D. , Wiley Dorothy J. , Minkoff Howard , Reddy Susheel , Stammer Emily E. , Gillison Maura L. , D'Souza Gypsyamber
Published: April 2023

Abstract
Introduction: Human papillomavirus (HPV) is an important risk factor for oropharyngeal cancer. Individuals with human immunodeficiency virus (HIV) have higher oral HPV prevalence but the risk factors for oral HPV infection are not well understood for either HIV-positive or HIV-negative individuals.

Methods: This study was nested within the Multicenter AIDS Cohort Study (MACS; men) and Women Interagency HIV Study (WIHS; women) cohorts. Exfoliated oral epithelial cells were collected from 379 HIV-positive and 266 at-risk HIV-negative individuals using a rinse and gargle with Scope mouthwash. Samples were tested for 36 types of HPV DNA using PGMY09/11 consensus primers and reverse line blot hybridization. Risk factors for oral HPV infection were explored using logistic regression with generalized estimating equations in this cross-sectional analysis.

Results: Prevalent oral HPV infection was common (34%), including HPV16 infection in 5.7% of participants. HIV-positive individuals had increased odds of prevalent oral HPV infection compared with HIV-negative individuals [adjusted OR = 2.1; 95% confidence interval (CI), 1.6–2.8]. Risk factors for prevalent oral HPV differed in HIV-positive and HIV-negative participants. Among HIV-negative individuals, higher number of recent oral sex or rimming partners were strong risk factors for prevalent oral HPV infection (each Ptrend < 0.01). In contrast, among HIV-positive individuals, lower CD4 T-cell count (Ptrend < 0.001) and higher number of lifetime sexual partners (Ptrend = 0.03) were strong risk factors.

Conclusions: Oral HPV prevalence was elevated in HIV-positive individuals after controlling for differences in cigarette smoking and sexual behavior, supporting the possibility that HIV may affect the natural history of oral HPV.

Impact: Immunosuppression may contribute to increased persistence or progression of oral HPV infection. Cancer Epidemiol Biomarkers Prev; 21(1); 122–33. ©2011 AACR.
Data from Genetically Predicted Telomere Length is not Associated with Pancreatic Cancer Risk
Authors: Antwi Samuel O. , Bamlet William R. , Broderick Brendan T. , Chaffee Kari G. , Oberg Ann , Jatoi Aminah , Boardman Lisa A. , Petersen Gloria M.
Published: April 2023

Abstract
Background: Epidemiologic associations of leukocyte telomere length (LTL) and pancreatic ductal adenocarcinoma (PDAC) have been inconsistent owing, in part, to variation in telomere length (TL) assessment across studies. To overcome this limitation and address concerns of potential reverse causation, we used carriage of telomere-related alleles to genetically predict TL and examined its association with PDAC.

Methods: A case–control study of 1,500 PDAC cases and 1,500 controls, frequency-matched on age and sex was performed. Eight of nine polymorphisms previously associated with variation in LTL were analyzed. Genetic risk scores (GRS) consisting of the TL-related polymorphisms were computed as the number of long TL alleles carried by an individual scaled to published kilobase pairs of TL associated with each allele. Participants were further categorized on the basis of the number of short TL alleles they carry across all eight SNPs. Associations were examined in additive and dominant models using logistic regression to calculate ORs and 95% confidence intervals (CI).

Results: In age- and sex-adjusted models, one short TL allele (rs10936599, T) was associated with reduced risk, whereas another short TL allele (rs2736100, A) was associated with increased risk, with per-allele ORs of 0.89 (95% CI, 0.79–0.99) and 1.13 (95% CI, 1.01–1.24), respectively. No association was observed with GRS or short TL allele counts, and no associations were observed in the dominant models.

Conclusions: Findings suggest that genetically predicted short TL is not associated with PDAC risk.

Impact: Common genetic determinants of short TL do not appear to influence PDAC risk. Cancer Epidemiol Biomarkers Prev; 26(6); 971–4. ©2017 AACR.
Data from Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992–2013
Authors: Noone Anne-Michelle , Cronin Kathleen A. , Altekruse Sean F. , Howlader Nadia , Lewis Denise R. , Petkov Valentina I. , Penberthy Lynne
Published: April 2023

Abstract
Background: Cancers are heterogeneous, comprising distinct tumor subtypes. Therefore, presenting the burden of cancer in the population and trends over time by these tumor subtypes is important to identify patterns and differences in the occurrence of these subtypes, especially to generalize findings to the U.S. general population.

Methods: Using SEER Cancer Registry Data, we present incidence rates according to subtypes for diagnosis years (1992–2013) among men and women for five major cancer sites: breast (female only), esophagus, kidney and renal pelvis, lung and bronchus, and thyroid. We also describe estimates of 5-year relative survival according to subtypes and diagnosis year (1992–2008). We used Joinpoint models to identify years when incidence rate trends changed slope. Finally, recent 5-year age-adjusted incidence rates (2009–2013) are presented for each subtype by race and age.

Results: Hormone receptor–positive and HER2-negative was the most common subtype (about 74%) of breast cancers. Adenocarcinoma made up about 69% of esophagus cases among men. Adenocarcinoma also is the most common lung subtype (43% in men and 52% in women). Ninety percent of thyroid subtypes were papillary. Distinct incidence and survival patterns emerged by these subtypes over time among men and women.

Conclusions: Histologic or molecular subtype revealed different incidence and/or survival trends that are masked when cancer is considered as a single disease on the basis of anatomic site.

Impact: Presenting incidence and survival trends by subtype, whenever possible, is critical to provide more detailed and meaningful data to patients, providers, and the public. Cancer Epidemiol Biomarkers Prev; 26(4); 632–41. ©2016 AACR.
Data from Population-Based Study of the Association of Variants in Mismatch Repair Genes with Prostate Cancer Risk and Outcomes
Authors: Langeberg Wendy J. , Kwon Erika M. , Koopmeiners Joseph S. , Ostrander Elaine A. , Stanford Janet L.
Published: April 2023

Abstract
Background: Mismatch repair (MMR) gene activity may be associated with prostate cancer risk and outcomes. This study evaluated whether single nucleotide polymorphisms (SNP) in key MMR genes are related to prostate cancer outcomes.

Methods: Data from two population-based case-control studies of prostate cancer among Caucasian and African-American men residing in King County, Washington were combined for this analysis. Cases (n = 1,458) were diagnosed with prostate cancer in 1993 to 1996 or 2002 to 2005 and were identified through the Seattle-Puget Sound Surveillance Epidemiology and End Results cancer registry. Controls (n = 1,351) were age-matched to cases and were identified through random digit dialing. Logistic regression was used to assess the relationship between haplotype-tagging SNPs and prostate cancer risk and disease aggressiveness. Cox proportional hazards regression was used to assess the relationship between SNPs and prostate cancer recurrence and prostate cancer–specific death.

Results: Nineteen SNPs were evaluated in the key MMR genes: five in MLH1, 10 in MSH2, and 4 in PMS2. Among Caucasian men, one SNP in MLH1 (rs9852810) was associated with overall prostate cancer risk [odds ratio, 1.21; 95% confidence interval (95% CI), 1.02, 1.44; P = 0.03], more aggressive prostate cancer (odds ratio, 1.49; 95% CI, 1.15, 1.91; P < 0.01), and prostate cancer recurrence (hazard ratio, 1.83; 95% CI, 1.18, 2.86; P < 0.01), but not prostate cancer–specific mortality. A nonsynonymous coding SNP in MLH1, rs1799977 (I219V), was also found to be associated with more aggressive disease. These results did not remain significant after adjusting for multiple comparisons.

Conclusion: This population-based case-control study provides evidence for a possible association with a gene variant in MLH1 in relation to the risk of overall prostate cancer, more aggressive disease, and prostate cancer recurrence, which warrants replication. Cancer Epidemiol Biomarkers Prev;19(1); OF1–7
Data from Global Cancer Incidence and Mortality Rates and Trends—An Update
Authors: Torre Lindsey A. , Siegel Rebecca L. , Ward Elizabeth M. , Jemal Ahmedin
Published: April 2023

Abstract
There are limited published data on recent cancer incidence and mortality trends worldwide. We used the International Agency for Research on Cancer's CANCERMondial clearinghouse to present age-standardized cancer incidence and death rates for 2003–2007. We also present trends in incidence through 2007 and mortality through 2012 for select countries from five continents. High-income countries (HIC) continue to have the highest incidence rates for all sites, as well as for lung, colorectal, breast, and prostate cancer, although some low- and middle-income countries (LMIC) now count among those with the highest rates. Mortality rates from these cancers are declining in many HICs while they are increasing in LMICs. LMICs have the highest rates of stomach, liver, esophageal, and cervical cancer. Although rates remain high in HICs, they are plateauing or decreasing for the most common cancers due to decreases in known risk factors, screening and early detection, and improved treatment (mortality only). In contrast, rates in several LMICs are increasing for these cancers due to increases in smoking, excess body weight, and physical inactivity. LMICs also have a disproportionate burden of infection-related cancers. Applied cancer control measures are needed to reduce rates in HICs and arrest the growing burden in LMICs.Cancer Epidemiol Biomarkers Prev; 25(1); 16–27. ©2015 AACR.

See related commentary by Bray, p. 3
Data from Cancer Incidence and Mortality during the Intervention and Postintervention Periods of the Women's Health Initiative Dietary Modification Trial
Authors: Thomson Cynthia A. , Van Horn Linda , Caan Bette J. , Aragaki Aaron K. , Chlebowski Rowan T. , Manson JoAnn E. , Rohan Thomas E. , Tinker Lesley F. , Kuller Lewis H. , Hou Lifang , Lane Dorothy S. , Johnson Karen C. , Vitolins Mara Z. , Prentice Ross L.
Published: April 2023

Abstract
Background: The Women's Health Initiative (WHI) low-fat (20% kcal) dietary modification (DM) trial (1993–2005) demonstrated a nonsignificant reduction in breast cancer, a nominally significant reduction in ovarian cancer, and no effect on other cancers (mean 8.3 years intervention). Consent to nonintervention follow-up was 83% (n = 37,858). This analysis was designed to assess postintervention cancer risk in women randomized to the low-fat diet (40%) versus usual diet comparison (60%).

Methods: Randomized, controlled low-fat diet intervention for prevention of breast and colorectal cancers conducted in 48,835 postmenopausal U.S. women, ages 50 to 79 years at 40 U.S. sites. Outcomes included total invasive cancer, breast cancer, and colorectal cancer, and cancer-specific and overall mortality.

Results: There were no intervention effects on invasive breast or colorectal cancer, other cancers, or cancer-specific or overall mortality during the postintervention period or the combined intervention and follow-up periods. For invasive breast cancer, the hazard ratios (HR) and 95% confidence interval (CI) were 0.92 (0.84–1.01) during intervention, 1.08 (0.94–1.24) during the postintervention period, and 0.97 (0.89–1.05) during cumulative follow-up. A reduced risk for estrogen receptor positive/progesterone receptor–negative tumors was demonstrated during follow-up. In women with higher baseline fat intake (quartile), point estimates of breast cancer risk were HR, 0.76 (95% CI, 0.62–0.92) during intervention versus HR, 1.11 (95% CI, 0.84–1.4) during postintervention follow-up (Pdiff = 0.03).

Conclusions: Dietary fat intake increased postintervention in intervention women; no long-term reduction in cancer risk or mortality was shown in the WHI DM trial.

Impact: Dietary advisement to reduce fat for cancer prevention after menopause generally was not supported by the WHI DM trial. Cancer Epidemiol Biomarkers Prev; 23(12); 2924–35. ©2014 AACR.
Data from Breast Cancer Subtypes and Previously Established Genetic Risk Factors: A Bayesian Approach
Authors: O'Brien Katie M. , Cole Stephen R. , Engel Lawrence S. , Bensen Jeannette T. , Poole Charles , Herring Amy H. , Millikan Robert C.
Published: April 2023

Abstract
Background: Gene expression analyses indicate that breast cancer is a heterogeneous disease with at least five immunohistologic subtypes. Despite growing evidence that these subtypes are etiologically and prognostically distinct, few studies have investigated whether they have divergent genetic risk factors. To help fill in this gap in our understanding, we examined associations between breast cancer subtypes and previously established susceptibility loci among white and African-American women in the Carolina Breast Cancer Study.

Methods: We used Bayesian polytomous logistic regression to estimate ORs and 95% posterior intervals for the association between each of 78 single nucleotide polymorphisms (SNP) and five breast cancer subtypes. Subtypes were defined using five immunohistochemical markers: estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptors 1 and 2 (HER1/2), and cytokeratin (CK) 5/6.

Results: Several SNPs in TNRC9/TOX3 were associated with luminal A (ER/PR+, HER2−) or basal-like breast cancer (ER−, PR−, HER2−, HER1, or CK 5/6+), and one SNP (rs3104746) was associated with both. SNPs in FGFR2 were associated with luminal A, luminal B (ER/PR+, HER2+), or HER2+/ER− disease, but none were associated with basal-like disease. We also observed subtype differences in the effects of SNPs in 2q35, 4p, TLR1, MAP3K1, ESR1, CDKN2A/B, ANKRD16, and ZM1Z1.

Conclusion and Impact: We found evidence that genetic risk factors for breast cancer vary by subtype and further clarified the role of several key susceptibility genes. Cancer Epidemiol Biomarkers Prev; 23(1); 84–97. ©2013 AACR.
Supplementary Figure Legend 1 from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
Authors: Stutterheim Janine , Ichou Fatima Ait , den Ouden Emmy , Versteeg Rogier , Caron Huib N. , Tytgat Godelieve A.M. , van der Schoot C. Ellen
Published: April 2023

PDF file - 55K
Supplementary Table 1 from Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer
Authors: Hardy Nancy M. , Mossoba Miriam E. , Steinberg Seth M. , Fellowes Vicki , Yan Xiao-Yi , Hakim Frances T. , Babb Rebecca R. , Avila Daniele , Gea-Banacloche Juan , Sportès Claude , Levine Bruce L. , June Carl H. , Khuu Hahn M. , Carpenter Ashley E. , Krumlauf Michael C. , Dwyer Andrew J. , Gress Ronald E. , Fowler Daniel H. , Bishop Michael R.
Published: April 2023

PDF file - 24K
Supplementary Methods, Figure Legends 1-4, Tables 1-4 from Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features
Authors: Tzelepi Vassiliki , Zhang Jiexin , Lu Jing-Fang , Kleb Brittany , Wu Guanglin , Wan Xinhai , Hoang Anh , Efstathiou Eleni , Sircar Kanishka , Navone Nora M. , Troncoso Patricia , Liang Shoudan , Logothetis Christopher J. , Maity Sankar N. , Aparicio Ana M.
Published: April 2023

PDF file - 178K
Supplementary Table 6A from High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Authors: Schulte Johannes H. , Bachmann Hagen S. , Brockmeyer Bent , DePreter Katleen , Oberthür André , Ackermann Sandra , Kahlert Yvonne , Pajtler Kristian , Theissen Jessica , Westermann Frank , Vandesompele Jo , Speleman Frank , Berthold Frank , Eggert Angelika , Brors Benedikt , Hero Barbara , Schramm Alexander , Fischer Matthias
Published: April 2023

XLS file - 56K
Supplementary Figure 1 from Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Authors: Hudecek Michael , Lupo-Stanghellini Maria-Teresa , Kosasih Paula L. , Sommermeyer Daniel , Jensen Michael C. , Rader Christoph , Riddell Stanley R.
Published: April 2023

PDF File - 129K, Supplementary Figure 1: Design of ROR1-CARs with modified spacer length and derived from the 2A2 and R12 scFV with different affinity.
Supplementary Table 4 from Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2
Authors: Chung Ling-Yen , Tang Shye-Jye , Sun Guang-Huan , Chou Teh-Ying , Yeh Tien-Shun , Yu Sung-Liang , Sun Kuang-Hui
Published: April 2023

PDF file, 61KB, Sequences of primer pairs used in quantitative reverse-transcription polymerase chain reaction (RT-qPCR).
Supplementary Figure 1 from Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2
Authors: Chung Ling-Yen , Tang Shye-Jye , Sun Guang-Huan , Chou Teh-Ying , Yeh Tien-Shun , Yu Sung-Liang , Sun Kuang-Hui
Published: April 2023

PDF file, 139KB, IHC staining and cell proliferation of NSCLC.
Supplementary Methods from Cyclophosphamide Induces a Type I Interferon–Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy
Authors: Moschella Federica , Torelli Giovanni Fernando , Valentini Mara , Urbani Francesca , Buccione Carla , Petrucci Maria Teresa , Natalino Fiammetta , Belardelli Filippo , Foà Robin , Proietti Enrico
Published: April 2023

PDF file - 65K, List of primers for GAPDH, BAFF, CLEC10A, IRF5, MARCO, CXCL10 and CCL2 Real-time PCR experiments.
Supplementary Table 2 from Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro
Authors: Kahlert Christoph , Lahes Saleh , Radhakrishnan Praveen , Dutta Shamik , Mogler Carolin , Herpel Esther , Brand Karsten , Steinert Gunnar , Schneider Martin , Mollenhauer Martin , Reissfelder Christoph , Klupp Fee , Fritzmann Johannes , Wunder Christina , Benner Axel , Kloor Matthias , Huth Cathrin , Contin Pietro , Ulrich Alexis , Koch Moritz , Weitz Jürgen
Published: April 2023

PDF file - 55K, Expression fold-change of EMT-associated genes and microRNAs between the four compartments liver (L). liver invasion front (LIF). tumor invasion frot (TIF) and tumor center (Tc). All samples were normalized to 18s expression and fold change expression was calculated according to the 2-��ct method as described previously (15). P-Values (P) were assessed by using the Wilcoxon signed-rank test. (LIF vs. L: expression fold-change of target gene in liver invasion front compared to liver. LIF vs TIF: expression fold-change of target gene in liver invasion front compared to tumor invasion front. LIF vs Tc: expression fold-change of target gene in liver invasion front compared to tumor center. TIF vs L: expression fold-change of target gene in tumor invasion front compared to liver. TIF vs Tc: expression fold-change of target gene in tumor invasion front compared to tumor center. L vs Tc: expression fold-change of target gene in liver compared to tumor center).
Supplementary Figure 3 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Authors: Kienast Yvonne , Klein Christian , Scheuer Werner , Raemsch Romi , Lorenzon Erica , Bernicke Dirk , Herting Frank , Yu Sidney , The Huynh Hung , Martarello Laurent , Gassner Christian , Stubenrauch Kay-Gunnar , Munro Kate , Augustin Hellmut G. , Thomas Markus
Published: April 2023

PDF file 201K, A2V CrossMab characterization and safety profile
Supplementary Figure S6 from Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia
Authors: Conrad David P. , Tsang Jovian , Maclean Meaghan , Diallo Jean-Simon , Le Boeuf Fabrice , Lemay Chantal G. , Falls Theresa J. , Parato Kelley A. , Bell John C. , Atkins Harold L.
Published: April 2023

Supplementary Figure S6 - PDF file 597K, Activated L1210 cells
Supplementary Figure S5 from Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia
Authors: Conrad David P. , Tsang Jovian , Maclean Meaghan , Diallo Jean-Simon , Le Boeuf Fabrice , Lemay Chantal G. , Falls Theresa J. , Parato Kelley A. , Bell John C. , Atkins Harold L.
Published: April 2023

Supplementary Figure S5 - PDF file 1161K, iLOV induces leukemia-specific immunity
Supplementary Methods from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer
Authors: Deng Yong-Jian , Tang Na , Liu Chao , Zhang Jiang-Yu , An Sheng-Li , Peng Yin-Li , Ma Li-Li , Li Guang-Qiu , Jiang Qiang , Hu Chun-Ting , Wang Ya-Nan , Liang Yao-Ze , Bian Xiu-Wu , Fang Wei-Gang , Ding Yan-Qing
Published: April 2023

PDF file - 191K
Supplementary Tables 3 and 4 from Novel Clinically Relevant Genes in Gastrointestinal Stromal Tumors Identified by Exome Sequencing
Authors: Schoppmann Sebastian F. , Vinatzer Ursula , Popitsch Niko , Mittlböck Martina , Liebmann-Reindl Sandra , Jomrich Gerd , Streubel Berthold , Birner Peter
Published: April 2023

PDF file, 24K, Supplemental Table 3 Variants per sample Supplemental Table 4 Variants unique per normal/cancer pair.
Supplementary Figure 3 from FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
Authors: Singh Mamata , Leasure Justin M. , Chronowski Christopher , Geier Brian , Bondra Kathryn , Duan Wenrui , Hensley Lauren A. , Villalona-Calero Miguel , Li Ning , Vergis Anthony M. , Kurmasheva Raushan T. , Shen Changxian , Woods Gary , Sebastian Nikhil , Fabian Denise , Kaplon Rita , Hammond Sue , Palanichamy Kamalakannan , Chakravarti Arnab , Houghton Peter J.
Published: April 2023

PDF file - 45KB, Radiation sensitivity after FANCD2 knockdown.
Supplementary Table 1 from Overexpression of Ecdysoneless in Pancreatic Cancer and Its Role in Oncogenesis by Regulating Glycolysis
Authors: Dey Parama , Rachagani Satyanarayana , Chakraborty Subhankar , Singh Pankaj K. , Zhao Xiangshan , Gurumurthy Channabasavaiah Basavaraju , Anderson Judy M. , Lele Subodh , Hollingsworth Michael A. , Band Vimla , Batra Surinder K.
Published: April 2023

XLSX file - 10K, Ecd expression in normal pancreas and various histological types of pancreas cancer
Related Article from Choosing Phase II Endpoints and Designs: Evaluating the Possibilities
Authors: LeBlanc Michael , Tangen Catherine
Published: April 2023

Related Article from Choosing Phase II Endpoints and Designs: Evaluating the Possibilities
Supplementary Figure 1 from Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer
Authors: Gupta Sonal , Pramanik Dipankar , Mukherjee Radha , Campbell Nathaniel R. , Elumalai Sathyanarayanan , de Wilde Roeland F. , Hong Seung-Mo , Goggins Michael G. , De Jesus-Acosta Ana , Laheru Daniel , Maitra Anirban
Published: April 2023

PDF file - 125K
Supplementary Table 2 from Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models
Authors: Zhang Cathy C. , Pavlicek Adam , Zhang Qin , Lira Maruja E. , Painter Cory L. , Yan Zhengming , Zheng Xianxian , Lee Nathan V. , Ozeck Mark , Qiu Ming , Zong Qing , Lappin Patrick B. , Wong Anthony , Rejto Paul A. , Smeal Tod , Christensen James G.
Published: April 2023

XLS file, 361K, Normalized NanoString expression values used in the analysis.
Supplementary Figures 1 - 5 from Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models
Authors: Zhang Cathy C. , Pavlicek Adam , Zhang Qin , Lira Maruja E. , Painter Cory L. , Yan Zhengming , Zheng Xianxian , Lee Nathan V. , Ozeck Mark , Qiu Ming , Zong Qing , Lappin Patrick B. , Wong Anthony , Rejto Paul A. , Smeal Tod , Christensen James G.
Published: April 2023

PDF file, 166K, Figure 1S. Differentially expressed genes between most sensitive and resistant models; Figure 2SA. Top genes differentially modulated gene between CC1599 and the remaining models; Figure 2SB. Unsupervised of cell cycle gene modulation after treatment; Figure 3S. Plots of correlation between gene modulation after treatment and baseline expression; Figure 4S. Correlation between modulation after treatment and TGI; Figure 5S. Correlation between TGI and Notch-10 score. Comparison between the Notch-10 score and tumor growth inhibition.
Supplementary Table 1 from Chromosomal Instability Substantiates Poor Prognosis in Patients with Diffuse Large B-cell Lymphoma
Authors: Bakhoum Samuel F. , Danilova Olga V. , Kaur Prabhjot , Levy Norman B. , Compton Duane A.
Published: April 2023

XLS file - 72K
Supplemental Material Section S8 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Authors: Calura Enrica , Fruscio Robert , Paracchini Lara , Bignotti Eliana , Ravaggi Antonella , Martini Paolo , Sales Gabriele , Beltrame Luca , Clivio Luca , Ceppi Lorenzo , Di Marino Mariacristina , Fuso Nerini Ilaria , Zanotti Laura , Cavalieri Duccio , Cattoretti Giorgio , Perego Patrizia , Milani Rodolfo , Katsaros Dionyssios , Tognon Germana , Sartori Enrico , Pecorelli Sergio , Mangioni Costantino , D'Incalci Maurizio , Romualdi Chiara , Marchini Sergio
Published: April 2023

PDF file - 127K, miR-192 and miR-194 expression values stratified according to tumor grade and survival analysis (OS and PFS). Data shown refers to the entire cohort of 67 stage I mucinous EOC patients.
Supplementary Table 1 from Characterization of Gene Amplification–Driven SKP2 Overexpression in Myxofibrosarcoma: Potential Implications in Tumor Progression and Therapeutics
Authors: Li Chien-Feng , Wang Ju-Ming , Kang Hong-Yo , Huang Chiung-Kuei , Wang Jun-Wen , Fang Fu-Min , Wang Yu-Hui , Wu Wen-Ren , Li Shau-Hsuan , Yu Shih-Chen , Lee Jen-Chieh , Lan Jui , Shiue Yow-Ling , Wu Li-Ching , Huang Hsuan-Ying
Published: April 2023

PDF file - 260K
Supplementary Figure 4 from Characterization of Gene Amplification–Driven SKP2 Overexpression in Myxofibrosarcoma: Potential Implications in Tumor Progression and Therapeutics
Authors: Li Chien-Feng , Wang Ju-Ming , Kang Hong-Yo , Huang Chiung-Kuei , Wang Jun-Wen , Fang Fu-Min , Wang Yu-Hui , Wu Wen-Ren , Li Shau-Hsuan , Yu Shih-Chen , Lee Jen-Chieh , Lan Jui , Shiue Yow-Ling , Wu Li-Ching , Huang Hsuan-Ying
Published: April 2023

PDF file - 353K, Results of wound healing assay reveal that the capability of wound closure is significantly impaired in both stable SKP2-knockdown OH931 (upper panels) and NMFH-1 (lower panels) cell lines, indicating the promigratory function of SKP2. Experiments were performed in triplicate and results expressed as mean � SD.
Supplementary Figure 2 from Characterization of Gene Amplification–Driven SKP2 Overexpression in Myxofibrosarcoma: Potential Implications in Tumor Progression and Therapeutics
Authors: Li Chien-Feng , Wang Ju-Ming , Kang Hong-Yo , Huang Chiung-Kuei , Wang Jun-Wen , Fang Fu-Min , Wang Yu-Hui , Wu Wen-Ren , Li Shau-Hsuan , Yu Shih-Chen , Lee Jen-Chieh , Lan Jui , Shiue Yow-Ling , Wu Li-Ching , Huang Hsuan-Ying
Published: April 2023

PDF file - 87K, As compared to the KEL-FIB dermal fibroblasts, more abundant endogenous SKP2 expression is detected in NMFH1 (SKP2-amplified) and OH931 (SKP2-nonamplififed) cell lines at both mRNA (left) and protein (right) levels.
Supplementary Figure 1 from Characterization of Gene Amplification–Driven SKP2 Overexpression in Myxofibrosarcoma: Potential Implications in Tumor Progression and Therapeutics
Authors: Li Chien-Feng , Wang Ju-Ming , Kang Hong-Yo , Huang Chiung-Kuei , Wang Jun-Wen , Fang Fu-Min , Wang Yu-Hui , Wu Wen-Ren , Li Shau-Hsuan , Yu Shih-Chen , Lee Jen-Chieh , Lan Jui , Shiue Yow-Ling , Wu Li-Ching , Huang Hsuan-Ying
Published: April 2023

PDF file - 73K, In pure sarcoma cells from 16 fresh specimens tested, the SKP2 mRNA expression folds have good concordance with gene dosage with correlation coefficient of R=0.591 and p-value <0.05.
Supplementary Figure 1 from Establishment and Characterization of Novel Cell Lines from Sinonasal Undifferentiated Carcinoma
Authors: Takahashi Yoko , Kupferman Michael E. , Bell Diana , Jiffar Tilahun , Lee June Goo , Xie Tong-Xin , Li Ning-Wei , Zhao Mei , Frederick Mitchell J. , Gelbard Alexander , Myers Jeffrey N. , Hanna Ehab Y.
Published: April 2023

PDF file - 79K, Cytogenetic analysis of the MDA8788-7 cell line. Representative G-banding of MDA8788-7 showed the same translocation in MDA8788-6; m1 t (1:17), m2 t (1:22), m3 t (1:15), m4 t (2:12), m5 t (4:15), m6 t (3:6), m7 t (8:19), m8 t (9:10), m9 t (9:16), m10 t (13:13), m11 t (14, 14) and m12 t (18:19).
Supplementary Figure 2 from FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51
Authors: Zhang Nu , Wu Xinjian , Yang Lixuan , Xiao Feizhe , Zhang Heng , Zhou Aidong , Huang Zhengsong , Huang Suyun
Published: April 2023

PDF file - 155K, Supplementary Fig.2. Recurrent GBM cells exhibit resistance to TMZ treatment
Supplementary Figure 2 from hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer
Authors: Wittinger Michael , Vanhara Petr , El-Gazzar Ahmed , Savarese-Brenner Bettina , Pils Dietmar , Anees Mariam , Grunt Thomas W. , Sibilia Maria , Holcmann Martin , Horvat Reinhard , Schemper Michael , Zeillinger Robert , Schöfer Christian , Dolznig Helmut , Horak Peter , Krainer Michael
Published: April 2023

PDF file - 68K
Supplementary Figure 1 from Targeted Therapy for BRAFV600E Malignant Astrocytoma
Authors: Nicolaides Theodore P. , Li Huifang , Solomon David A. , Hariono Sujatmi , Hashizume Rintaro , Barkovich Krister , Baker Suzanne J. , Paugh Barbara S. , Jones Chris , Forshew Tim , Hindley Guy F. , Hodgson J. Graeme , Kim Jung-Sik , Rowitch David H. , Weiss William A. , Waldman Todd A. , James C. David
Published: April 2023

PDF file - 115K
Supplementary Figures 1 - 11 from Expression Profiling of Archival Tumors for Long-term Health Studies
Authors: Waldron Levi , Ogino Shuji , Hoshida Yujin , Shima Kaori , McCart Reed Amy E. , Simpson Peter T. , Baba Yoshifumi , Nosho Katsuhiko , Segata Nicola , Vargas Ana Cristina , Cummings Margaret C. , Lakhani Sunil R. , Kirkner Gregory J. , Giovannucci Edward , Quackenbush John , Golub Todd R. , Fuchs Charles S. , Parmigiani Giovanni , Huttenhower Curtis
Published: April 2023

PDF file - 1787K, Supplemental Figure S1: Immunohistochemistry for selected proteins. Supplemental Figure S2: Pairwise scatterplots of technical variables for 1,003 DASL arrays from the NHS/HPFS study, including median value of Illumina control probes, sample age, RNA concentration, fraction of probes called present (p<0.05), and Interquartile Range (IQR). Supplemental Figure S3: Spatial distribution of sample-independent positive control probes (CY3_HYB) across the 12 96-well plates of the NHS/HPFS experiment. Supplemental Figure S4: Spearman correlation of expression profiles of individual technical replicates to the median pseudochip decreases with Interquartile Range (IQR), particularly for samples with IQR less than 1. Supplemental Figure S5: CAT-boxplots for six covariates available in the NHS/HPFS study, showing reproducibility of ranked lists of differentially expressed between two independent samples by plotting fractional concordance of the top n genes in each list on the y-axis, against n on the x-axis. Supplemental Figure S6: Examples of two of the "best" (0.1% and 0.2% quantile) and "worst" (99.8% and 99.9% quantile) probes for reproducibility as assessed by Spearman correlation, Euclidian Distance, and Manhattan Distance. Supplemental Figure S7: Reproducibility of individual probe intensity measurements. For samples passing quality control in the BC/A experiment, Spearman correlation between technical replicates was calculated for each probe, as a function of four different measures of probe activity. Supplemental Figure S8: Analysis of probe reproducibility measured by Euclidian distance, and relationships between different probe filtering criteria. Supplemental Figure S9: t-statistics using samples passing strict QC and permissive QC for the molecular markers considered in Supplemental Table 1. Supplemental Figure S10: validation of MSI-associated mRNA transcripts previously reported from fresh-frozen tissues(24). Supplemental Figure S11: Distribution of presence calls (fraction of samples in which a probe is called present, p<0.01) for all 24,526 probes on the DASL� assay, and for probes involved in validation of previously identified MSI-associated gene transcripts(24).
Supplementary Figure 6 from Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy
Authors: McCourt Clare , Maxwell Pamela , Mazzucchelli Roberta , Montironi Rodolfo , Scarpelli Marina , Salto-Tellez Manuel , O'Sullivan Joe M. , Longley Daniel B. , Waugh David J.J.
Published: April 2023

PDF file, 175KB, Castrate-resistant cells are insensitive to bicalutamide and SAHA.
Supplementary Figure 2 from Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Authors: Van Cutsem Eric , Eng Cathy , Nowara Elzbieta , Świeboda-Sadlej Anna , Tebbutt Niall C. , Mitchell Edith , Davidenko Irina , Stephenson Joe , Elez Elena , Prenen Hans , Deng Hongjie , Tang Rui , McCaffery Ian , Oliner Kelly S. , Chen Lisa , Gansert Jennifer , Loh Elwyn , Smethurst Dominic , Tabernero Josep
Published: April 2023

PDF file - 38K, Supplemental Fig. S2. Best percent change of the sum of longest diameters of target lesions from baseline to post-baseline. (A) Panitumumab plus rilotumumab.(B) Panitumumab plus ganitumab. (C) Panitumumab alone.
Supplementary Figure 3 from Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy
Authors: McCourt Clare , Maxwell Pamela , Mazzucchelli Roberta , Montironi Rodolfo , Scarpelli Marina , Salto-Tellez Manuel , O'Sullivan Joe M. , Longley Daniel B. , Waugh David J.J.
Published: April 2023

PDF file, 214KB, SAHA targets the AR pathway in androgen-dependent CaP cells.